Another therapeutic strategy that demonstrated antitumor activity in Asian patients with acral and mucosal melanoma after the failure of conventional treatment was the combination of an alkylating agent, temozolomide, with the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor, apatinib [39]. This evidence concerns the gene KDR and mucosal melanoma.